Arthur Tzianabos sold $7,445 of QTTB
director at Q32 Bio Inc.. 13,037 shares at an average of $0.57, traded Jan 9, 2024, filed Feb 15, 2024.
Score components
- +15RoleDirector
- 0Trade size$7k at market
- 0Share of holdings soldSold 9.2% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +27.2%, 3m +139.2%, 6m +182.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-015944, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 1, 2024 | MOption exercise Common Stock10b5-1 | +14,280 | - | - | 122,675 | Feb 15, 2024 |
| Jan 1, 2024 | MOption exercise Common Stock10b5-1 | +19,140 | - | - | 141,815 | Feb 15, 2024 |
| Jan 9, 2024 | SOpen-market sale Common Stock10b5-1 | -13,037 | $0.57 | $7,445 | 128,778 | Feb 15, 2024 |
| Jan 1, 2024 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -14,280 | $0.00 | $0 | 0 | Feb 15, 2024 |
| Jan 1, 2024 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -19,140 | $0.00 | $0 | 19,720 | Feb 15, 2024 |
Related signals
Other insiders at Q32 Bio Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | Q32 Bio Inc. | Lee Kalowski CFO and President | $66k 3,972 shares | -3% | |
| 51Moderate | Q32 Bio Inc. | Jodie Pope Morrison CEO | $163k 9,845 shares | -3% | |
| 36Weak | Q32 Bio Inc. | Shelia M. Violette Chief Scientific Officer | $46k 2,798 shares | -2% | |
| 57Moderate | Q32 Bio Inc. | Orbimed Advisors LLC director, owner | $15M 1,875,000 shares | +83% | |
| 62Notable | Q32 Bio Inc. | Diyong Xu director, owner | $15M 1,875,000 shares | +83% | |
| 42Moderate | Q32 Bio Inc. | Lee Kalowski CFO and President | $18k 3,995 shares | -10% | |
| 46Moderate | Q32 Bio Inc. | Jodie Pope Morrison CEO | $45k 9,896 shares | -10% | |
| 30Weak | Q32 Bio Inc. | Shelia M. Violette Chief Scientific Officer | $13k 2,815 shares | -5% | |
| 40Moderate | Q32 Bio Inc. | Lee Kalowski CFO and President | $31k 9,072 shares | -19% | |
| 47Moderate | Q32 Bio Inc. | Jodie Pope Morrison CEO | $78k 22,506 shares | -19% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.